# US 2025/0051305 A1 · Nitrogen-containing saturated heterocyclyl derivative

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0051305 A1
- Document ID: US20250051305A1
- Status: Published application
- Kind: A1
- Application number: 18/558,337
- Filed: 2023-07-28
- Published: 2025-02-13
- Earliest claimed: 2022-07-29
- Assignees: Sumitomo Pharma Co., Ltd.
- Applicants: Sumitomo Pharma Co., Ltd.
- Inventors: Hitoshi WATANABE; Shuya YAMADA; Katsushi KITAHARA; Mariko KOBAYASHI
- Web page: https://patentgrep.com/patent/US20250051305A1

## CPC

- C07D 405/14: containing three or more hetero rings
- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 31/4427: containing further heterocyclic ring systems
- A61K 31/4439: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465)
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 31/497: containing further heterocyclic rings
- A61K 31/501: not condensed and containing further heterocyclic rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/553: having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K 45/00: Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07D 401/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D 491/04: Ortho-condensed systems
- C07D 491/08: Bridged systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, which comprises as an active ingredient a compound of formula (1) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are hydrogen, etc., R3 and R4 are hydrogen, C1-6 alkyl, etc., R5 is halogen, C1-6 alkyl, etc., R6 is hydrogen, halogen, etc., X is oxygen, etc., Y is carbon, etc., m and n are an integer of 0, 1, etc., r and s are 0, 1, 2, etc., Hy is pyridine ring, etc., which has an action of suppressing or reducing the accumulation of abnormal aggregation of proteins in the brain.

## Claims

### Claim at position 1

1: A compound of formula (1):
or a pharmaceutically acceptable salt thereof, wherein
X is oxygen or NR7,
R7 is hydrogen, C1-3 alkyl optionally-substituted with 1 to 3 the same or different halogen atoms, or cyclopropyl,
Y is CH or nitrogen,
m is 0, 1, or 2,
n is 0 or 1,
r is 0, 1, 2, 3, or 4,
s is 0, 1, or 2,
provided that when s is 0, then Y is CH, and r is 1, 2, 3, or 4,
when s is 1, then Y is CH, and r is 0, 1, 2, or 3, and
when s is 2, then r is 1 or 2,
R1 is hydrogen, halogen, methyl, or hydroxy,
R2 is hydrogen, halogen, methyl, or hydroxy,
R3 is hydrogen, or C1-3 alkyl,
R4 is hydrogen, or C1-3 alkyl,
or, R3 and R4 may be optionally taken together to form a bridged methylene or a bridged ethylene,
R5 is halogen, C1-3 alkyl optionally-substituted with 1 to 3 the same or different halogen atoms, or C1-3 alkoxy optionally-substituted with 1 to 3 the same or different halogen atoms,
R6 is hydrogen, halogen, C1-3 alkyl optionally-substituted with 1 to 3 the same or different halogen atoms, or C1-3 alkoxy optionally-substituted with 1 to 3 the same or different halogen atoms, and
Hy is pyridine ring, pyridazine ring, pyrimidine ring, or pyrazine ring,
provided that
(I) when Hy accompanied with R5 and R6 is 5-fluoropyridin-2-yl, and m and n are 1, then r is 0, and s is 1,
(II) when Hy accompanied with R5 and R6 is 6-methoxypyridin-3-yl, m and n are 1, and X is oxygen, then r is 0, and s is 1,
(III) when Hy accompanied with R5 and R6 is 5-methoxypyridin-2-yl, m and n are 1, and X is NR7, then r is 0, and s is 1,
(IV) when R5 is methyl, and R6 is hydrogen, then r is 0, and s is 1,
but,
(I′) Hy accompanied with R5 and R6 is not 4,6-dimethylpyrimidin-2-yl, or 5-bromopyrimidin-2-yl,
(II′) when Hy accompanied with R5 and R6 is 5-chloropyridin-2-yl, then m and n are 1, and both R1 and R2 are not hydrogen,
provided that the following compounds are excluded
(III′) (1-isopropylpiperidin-4-yl)(3-(2-methoxypyridin-3-yl)pyrrolidin-1-yl)methanone, and
(IV′) (3-ethoxyoxetan-3-yl)[3-{4-(trifluoromethyl)pyrimidin-2-yl}pyrrolidin-1-yl]methanone.

### Claim at position 2 (depends on 1)

2: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein m is 1, and n is 1.

### Claim at position 3 (depends on 1)

3: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are independently hydrogen, methyl, or fluorine.

### Claim at position 4 (depends on 1)

4: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are hydrogen.

### Claim at position 5 (depends on 1)

5: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X is oxygen, NH, or NMe.

### Claim at position 6 (depends on 1)

6: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R3 is hydrogen.

### Claim at position 7 (depends on 1)

7: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R4 is methyl or ethyl.

### Claim at position 8 (depends on 1)

8: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Y is CH.

### Claim at position 9 (depends on 1)

9: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein s is 1.

### Claim at position 10 (depends on 1)

10: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein r is 0, and s is 1.

### Claim at position 11 (depends on 1)

11: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is presented in formula (2):
wherein
X is oxygen, NH, or NMe,
R4 is methyl or ethyl,
R5 is halogen, C1-3 alkyl optionally-substituted with 1 to 3 the same or different halogen atoms, or C1-3 alkoxy optionally-substituted with 1 to 3 the same or different halogen atoms,
R6 is hydrogen, halogen, C1-3 alkyl optionally-substituted with 1 to 3 the same or different halogen atoms, or C1-3 alkoxy optionally-substituted with 1 to 3 the same or different halogen atoms, and
Hy is pyridine ring, pyridazine ring, pyrimidine ring, or pyrazine ring,
provided that Hy accompanied with R5 and R6 is not 5-chloropyridin-2-yl.

### Claim at position 12 (depends on 1)

12: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Hy is pyridine ring.

### Claim at position 13 (depends on 1)

13: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R5 is trifluoromethyl.

### Claim at position 14 (depends on 1)

14: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Hy is pyridin-3-yl.

### Claim at position 15 (depends on 1)

15: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X is oxygen.

### Claim at position 16 (depends on 1)

16: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R4 is methyl.

### Claim at position 17 (depends on 1)

17: The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X is NH or NMe.

### Claim at position 18

18: The compound of claim or a pharmaceutically acceptable salt thereof, wherein X is NMe.

### Claim at position 19 (depends on 1)

19: The compound of claim 1 or a pharmaceutically acceptable salt thereof, selected from the following compounds:
(3-methyloxetan-3-yl){4-[6-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone,
(3-methyloxetan-3-yl)(4-[5-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone,
(3-methyloxetan-3-yl){4-[4-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone,
(3-methyloxetan-3-yl){4-[2-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone,
{4-[5-fluoro-6-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}(3-methyloxetan-3-yl)methanone,
(3-methyloxetan-3-yl){4-[4-methyl-6-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone,
(1,3-dimethylazetidin-3-yl){4-[6-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone,
(1,3-dimethylazetidin-3-yl){4-[2-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone,
(1,3-dimethylazetidin-3-yl){4-[4-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone, and
(1,3-dimethylazetidin-3-yl){4-[5-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone.

### Claim at position 20 (depends on 1)

20: The compound of claim 1 or a pharmaceutically acceptable salt thereof, selected from the following compounds:
(3-methyloxetan-3-yl){4-[6-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone,
(3-methyloxetan-3-yl){4-[5-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone,
{4-[5-fluoro-6-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}(3-methyloxetan-3-yl)methanone,
(3-methyloxetan-3-yl){4-[4-methyl-6-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone,
(1,3-dimethylazetidin-3-yl){4-[2-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone, and
(1,3-dimethylazetidin-3-yl){4-[5-(trifluoromethyl)pyridin-3-yl]piperidin-1-yl}methanone.

### Claim at position 21 (depends on 1)

21: A medicament comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

### Claim at position 22

22: A medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, comprising as an active ingredient a compound of formula (1):
wherein
X is oxygen or NR7,
R7 is hydrogen, C1-3 alkyl optionally-substituted with 1 to 3 the same or different halogen atoms, or cyclopropyl,
Y is CH or nitrogen,
m is 0, 1, or 2,
n is 0 or 1,
r is 0, 1, 2, 3, or 4,
s is 0, 1, or 2,
provided that when s is 0, then Y is CH, and r is 1, 2, 3, or 4,
when s is 1, then Y is CH, and r is 0, 1, 2, or 3, and
when s is 2, then r is 1 or 2,
R1 is hydrogen, halogen, methyl, or hydroxy,
R2 is hydrogen, halogen, methyl, or hydroxy,
R3 is hydrogen, or C1-3 alkyl,
R4 is hydrogen, or C1-3 alkyl,
or, R3 and R4 may be optionally taken together to form a bridged methylene or a bridged ethylene,
R5 is hydrogen, halogen, C1-3 alkyl optionally-substituted with 1 to 3 the same or different halogen atoms, or C1-3 alkoxy optionally-substituted with 1 to 3 the same or different halogen atoms,
R6 is hydrogen, halogen, C1-3 alkyl optionally-substituted with 1 to 3 the same or different halogen atoms, or C1-3 alkoxy optionally-substituted with 1 to 3 the same or different halogen atoms, and
Hy is pyridine ring, pyridazine ring, pyrimidine ring, or pyrazine ring, or a pharmaceutically acceptable salt thereof.

### Claim at position 23 (depends on 22)

23: The medicament of claim 22, wherein m is 1, and n is 1.

### Claim at position 24 (depends on 22)

24: The medicament of claim 22, wherein R1 and R2 are independently hydrogen, methyl, or fluorine.

### Claim at position 25 (depends on 22)

25: The medicament of claim 22, wherein R1 and R2 are hydrogen.

### Claim at position 26 (depends on 22)

26: The medicament of claim 22, wherein X is oxygen, NH, or NMe.

### Claim at position 27 (depends on 22)

27: The medicament of claim 22, wherein R3 is hydrogen.

### Claim at position 28 (depends on 22)

28: The medicament of claim 22, wherein R4 is methyl or ethyl.

### Claim at position 29 (depends on 22)

29: The medicament of claim 22, wherein Y is CH.

### Claim at position 30 (depends on 22)

30: The medicament of claim 22, wherein s is 1.

### Claim at position 31 (depends on 22)

31: The medicament of claim 22, wherein r is 0, and s is 1.

### Claim at position 32 (depends on 22)

32: The medicament of claim 22, wherein the compound is presented in formula (2):
wherein
X is oxygen, NH, or NMe,
R4 is methyl or ethyl,
R5 is hydrogen, halogen, C1-3 alkyl optionally-substituted with 1 to 3 the same or different halogen atoms, or C1-3 alkoxy optionally-substituted with 1 to 3 the same or different halogen atoms,
R6 is hydrogen, halogen, C1-3 alkyl optionally-substituted with 1 to 3 the same or different halogen atoms, or C1-3 alkoxy optionally-substituted with 1 to 3 the same or different halogen atoms, and
Hy is pyridine ring, pyridazine ring, pyrimidine ring, or pyrazine ring.

### Claim at position 33 (depends on 22)

33: The medicament of claim 22, wherein Hy is pyridine ring.

### Claim at position 34 (depends on 22)

34: The medicament of claim 22, wherein R5 is trifluoromethyl.

### Claim at position 35 (depends on 22)

35: The medicament of claim 22, wherein Hy is pyridin-3-yl.

### Claim at position 36 (depends on 22)

36: The medicament of claim 22, wherein X is oxygen.

### Claim at position 37 (depends on 22)

37: The medicament of claim 22, wherein R4 is methyl.

### Claim at position 38 (depends on 22)

38: The medicament of claim 22, wherein X is NH or NMe.

### Claim at position 39 (depends on 22)

39: The medicament of claim 22, wherein X is NMe.

### Claim at position 40 (depends on 22)

40: The medicament of claim 22, wherein the central nervous system disease is related to tau, α-synuclein, TDP-43, or polyglutamine.

### Claim at position 41 (depends on 22)

41: The medicament of claim 22, wherein the central nervous system disease is Alzheimer's disease, frontotemporal lobar degeneration, Parkinson's disease, dementia with Lewy body, multiple system atrophy, Gaucher disease, infantile neuroaxonal dystrophy, amyotrophic lateral sclerosis, Huntington's disease, or spinocerebellar ataxia.

### Claim at position 42 (depends on 22)

42: The medicament of claim 22, wherein the central nervous system disease is related to α-synuclein.

### Claim at position 43 (depends on 22)

43: The medicament of claim 22, wherein the central nervous system disease is Parkinson's disease, dementia with Lewy body, multiple system atrophy, Gaucher disease, or infantile neuroaxonal dystrophy.

### Claim at position 44 (depends on 22)

44: A medicament for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, comprising the compound of claim 22 or a pharmaceutically acceptable salt thereof in combination with at least one agent selected from L-dopa, a dopamine agonist, an MAO-B inhibitor, a catechol-O-methyltransferase (COMT) inhibitor, αSyn antibody, and a pharmaceutically acceptable salt thereof.

### Claim at position 45 (depends on 22)

45: A medicament comprising the compound of claim 22 or a pharmaceutically acceptable salt thereof, for treating or preventing central nervous system disease whose cause is related to abnormal aggregation of proteins in the brain, in combination with at least one agent selected from L-dopa, a dopamine agonist, an MAO-B inhibitor, a catechol-O-methyltransferase (COMT) inhibitor, αSyn antibody, and a pharmaceutically acceptable salt thereof.

### Claim at position 46

46: A process for preparing a compound of formula (3):
or a pharmaceutically acceptable salt thereof,
wherein
R4 is methyl or ethyl,
R5 is trifluoromethyl,
R6 is hydrogen, halogen, C1-3 alkyl optionally-substituted with 1 to 3 the same or different halogen atoms, or C1-3 alkoxy optionally-substituted with 1 to 3 the same or different halogen atoms, and
Hy is pyridin-3-yl,
comprising the following Step 1;
(Step 1)
condensing a compound of formula (4):
wherein R5, R6, and Hy are as defined above, or a salt thereof
with a compound of formula (5):
wherein R4 is as defined above, and A is OH or halogen,
or a salt thereof to prepare a compound of formula (3) or a pharmaceutically acceptable salt thereof.

### Claim at position 47

47: A process for preparing a compound of formula (6):
or a pharmaceutically acceptable salt thereof,
wherein
R4 is methyl,
R5 is trifluoromethyl,
R6 is hydrogen, halogen, C1-3 alkyl optionally-substituted with 1 to 3 the same or different halogen atoms, or C1-3 alkoxy optionally-substituted with 1 to 3 the same or different halogen atoms, and
Hy is pyridin-3-yl,
comprising the following Steps 1 to 3;
(Step 1)
condensing a compound of formula (4):
wherein R5, R6, and Hy are as defined above, or a salt thereof
with a compound of formula (7):
wherein R4 is as defined above, A is OH or halogen, and Pro is an amino-protecting group, or a salt thereof to prepare a compound of formula (8):
wherein R4, R5, R6, Hy, and Pro are as defined above, or a pharmaceutically acceptable salt thereof,
(Step 2)
deprotecting the amino-protecting group in the compound of formula (8) or a salt thereof to prepare a compound of formula (9):
wherein R4, R5, R6, and Hy are as defined above, or a salt thereof,
(Step 3)
reacting the compound of formula (9) or a salt thereof with formaldehyde or its equivalent compound in the presence of a reducing agent to prepare the compound of formula (6) or a pharmaceutically acceptable salt thereof.
